ProPSMA was a prospective clinical trial at 10 sites, evaluating [68Ga]Ga-PSMA-11 for primary staging of prostate cancer.7An unexpected 15% underestimation in standardized uptake values (SUV) (range: −23% to −13%) was found in 10/14 PET systems evaluated.8This was eventually identified to be due to an incorrect factory-shipped dose calibrator setting. This evidence concerns the gene FOLH1 and Familial prostate cancer.